Capstone Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Capstone Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$539K	Buy	20,964 +8,001	+62%	+$164K	﹤0.01%	1207
2026 Q1	$249K	Sell	12,963 -25,849	-67%	-$514K	﹤0.01%	1440
2025 Q4	$641K	Buy	+38,812	New	+$655K	﹤0.01%	1049
2024 Q2	–	Sell	-19,741	Closed	-$405K	–	2172
2024 Q1	$405K	Sell	19,741 -3,148	-14%	-$59.2K	﹤0.01%	1672
2023 Q4	$491K	Sell	22,889 -14,678	-39%	-$291K	﹤0.01%	1348
2023 Q3	$775K	Buy	+37,567	New	+$953K	﹤0.01%	1084

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's DNLI Position: Q2 2026 in Review

Capstone Investment Advisors increased its Denali Therapeutics (DNLI) stake by 62% in Q2 2026, buying an estimated $164K and bringing the position to 20,964 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #1207.

Capstone Investment Advisors first reported a position in DNLI in Q3 2023 and has held it in 6 quarters since. The position peaked at $775K in Q3 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Capstone Investment Advisors held 20,964 shares of Denali Therapeutics worth $539K as of Q2 2026.
Capstone Investment Advisors bought 8,001 Denali Therapeutics shares in Q2 2026, an estimated $164K.
Denali Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1207 holding.
Capstone Investment Advisors first reported a position in Denali Therapeutics in Q3 2023 and has held it in 6 quarters since.
Capstone Investment Advisors's Denali Therapeutics position peaked at $775K in Q3 2023.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.